For direct compression evaluations, the as-received 9-fluorenemethanol pharma grade API is first milled through a Comil U5 conical mill equipped with a 0.457 mm rasp screen at 2,500 rpm. The milling step is required because the primary particle population retains loose agglomerates above 180 µm as measured by dry laser diffraction at 2.0 bar on a Malvern Mastersizer 3000. No compendial monograph for 9-fluorenemethanol is currently published; therefore, blend acceptance is evaluated by general chapter methods instead of a fixed monograph. A representative starting formulation for a 200 mg tablet core is 4.50% w/w API, 62.50% w/w microcrystalline cellulose PH102, 32.50% w/w lactose monohydrate, 2.00% w/w croscarmellose sodium, and 0.50% w/w magnesium stearate. The microcrystalline cellulose and lactose are first charged to a 300 L bin blender and mixed at 18 rpm for 10 min. The API is pre-triturated in a 1:5 ratio with lactose for 3 min, passed through a 500 µm sieve, and added to the bin blender for 15 min at 18 rpm. Magnesium stearate is screened through a 250 µm sieve and blended for 3 min at 12 rpm. Compression is performed on a rotary tablet press with 9 mm round concave tooling at a main compression force of 8–12 kN, pre-compression 1.5 kN, and turret speed 40,000 tablets/h. Tablet cores are targeted to hardness 60–80 N on a Schleuniger 6D tester, friability not more than 0.8% w/w per USP <1216>, and disintegration not more than 10 min in 0.1 M HCl at 37 °C. Content uniformity is evaluated by USP <905> with acceptance value not more than 15. Dense roller compaction is avoided because localized frictional heating in the compaction zone can approach the melting point of the API; if a dry granulation route is unavoidable, product temperature is maintained below 30 °C by chilled rollers. The finished product is an immediate-release film-coated tablet using aqueous HPMC-based coating at 3.0% w/w weight gain. Compliance records follow 21 CFR 211.110 for in-process sampling and 21 CFR 211.65 for equipment contact surfaces.

Why Does Low-Dose Capsule Filling Require Two-Stage Geometric Dilution?

Because low-dose encapsulation leaves the API at a final mass ratio below 2.00% w/w, two-stage geometric dilution is required to limit cohesive fine adhesion to stainless-steel and polyurethane contact surfaces. A representative size 3 capsule formulation is 1.50% w/w API, 10.00% w/w pregelatinized starch, 86.00% w/w lactose monohydrate, 1.00% w/w colloidal silicon dioxide, and 1.50% w/w sodium stearyl fumarate. Stage one combines API with an equal mass of lactose in a 5 L V-blender at 25 rpm for 5 min; stage two adds an additional lactose mass equal to the first stage and blends for 5 min; the sequence continues until the total lactose fraction is incorporated. The final blend is passed through a 600 µm conical mill at 1,200 rpm to disperse agglomerates. Capsule filling on an MG2 Planeta dosator machine targets a fill weight of 180 mg per capsule with weight variation acceptance of ±5%, content uniformity by USP <905>, and disintegration by USP <701>. In-process sampling for blend uniformity is taken at 10 locations; the acceptance value is not more than 15. Disintegration is measured in 900 mL water at 37 °C for not more than 15 min. The control room is maintained at 35–45% RH to limit electrostatic charge. If the targeted dose falls below 1.0 mg per capsule, direct fill at the above ratios is not recommended because segregation risk and flow heterogeneity increase; a wet granulation route is introduced instead. The terminal finished product is a hard gelatin capsule intended for immediate drug release. Charge-in verification follows 21 CFR 211.101, and release records are reviewed under 21 CFR 211.160.

When Wet Granulation Solvent Ratio Drops Below 0.35 g/g, Hardness Uniformity Fails

In high-shear wet granulation of 9-fluorenemethanol tablets, the granulating solvent-to-dry-mass ratio is controlled between 0.35 g/g and 0.45 g/g. A representative formula is 2.00% w/w API, 68.00% w/w mannitol, 20.00% w/w microcrystalline cellulose, 6.00% w/w crospovidone, and 4.00% w/w povidone K30. The granulating fluid is a co-solvent composed of 60% w/w purified water, 30% w/w ethanol, and 10% w/w povidone K30. It is added at 0.38 g/g of dry mix. Processing in a Fielder PMA 250 high-shear granulator starts with dry blending for 5 min at impeller 150 rpm. The binder fluid is introduced over 2 min through a mass flow-controlled nozzle; wet massing continues at impeller 300 rpm and chopper 1,500 rpm for 3 min. Granules are dried in a fluid-bed dryer at inlet air 50 °C until loss on drying is not more than 2.0% w/w. Dried granules are milled through a 1.0 mm screen. Compression with 10 mm round tooling targets hardness 80–100 N, friability not more than 0.5% w/w, and disintegration not more than 10 min in purified water at 37 °C. Residual ethanol is controlled by USP <467> Option 1 with a limit of not more than 5,000 ppm, following ICH Q3C. The terminal dosage form is a film-coated tablet with an aqueous HPMC/PEG 3350 coating at 3.5% w/w weight gain. If the solvent ratio falls below 0.35 g/g, granule densification is incomplete and tablet hardness varies by more than 15 N across the batch; if the ratio exceeds 0.45 g/g, drying time increases and ethanol residue exceeds the 5,000 ppm limit. The acceptable operating window is therefore ±0.02 g/g around the target.

Fluid-bed granulation deposits micronized 9-fluorenemethanol onto sucrose and mannitol cores without the compacted granules produced by high-shear granulation. In a pilot-scale Glatt GPCG-3.1 unit with a 7 kg batch, the binder dispersion is prepared from hydroxypropyl methylcellulose 5 mPa·s at 8.0% w/w solids in deionized water. The API is suspended in the binder dispersion at 2.0% w/w of the final granule mass. The dry substrate consists of 75.0% w/w sucrose spheres, 12.0% w/w mannitol, 4.0% w/w polyethylene glycol 6000, 2.0% w/w talc, and 1.0% w/w colloidal silicon dioxide. Spray rate is set at 12 g/min, atomizing air pressure 2.0 bar, inlet air temperature 60 °C, and product temperature is held at 38–40 °C. After the spray phase, granules are dried until loss on drying is not more than 1.5% w/w and then passed through a 1.18 mm sieve. Fines below 125 µm are controlled to not more than 12% w/w to prevent a dusty reconstitution. A unit-dose sachet is filled at 1.0 g weight containing 20 mg API. The reconstituted suspension is prepared by adding 5 mL potable water; it must disperse within 2 min without foaming. The sachet is sealed in a foil-laminate package conforming to USP <671>. Uniformity of dosage units is assessed by USP <905>; moisture is determined by Karl Fischer titration.

Terminal Sterilization Is Not Applied to 10% Ethanol Co-Solvent Lyophilized Vials

For an injectable formulation of 9-fluorenemethanol pharma grade API, the low aqueous solubility of the neutral alcohol below 0.1 mg/mL in water at 25 °C drives a co-solvent-loaded lyophilized design. A representative vial composition is 2.0 mg/mL API in 20% v/v PEG-300, 10% v/v ethanol, 4.0% w/v mannitol, and water-for-injection to final volume. The pH is adjusted to 6.5 ± 0.2 with 0.1 M sodium hydroxide. Compounding is performed in a jacketed stainless-steel vessel under nitrogen at 35 °C. The API is first dissolved in the PEG-300/ethanol phase, and the mannitol is dissolved separately in water-for-injection. The solutions are combined and filtered through a 0.45 µm polypropylene pre-filter followed by a 0.22 µm PVDF membrane. Filling is performed into 10 mL type I borosilicate vials at 5.0 mL per vial. The lyophilization cycle uses a freezing ramp to -40 °C at 0.5 °C/min, holding for 4 h; primary drying at -20 °C shelf temperature and 0.6 mbar chamber pressure for 24 h; secondary drying at 25 °C and 0.05 mbar for 6 h. The resulting cake is reconstituted to 10 mg/vial with 5 mL water-for-injection. Residual moisture is limited to not more than 1.0% w/w by Karl Fischer. Terminal sterilization by moist heat is not applied unless container closure integrity and drug product stability are validated under ISO 17665-1; because the formulation contains ethanol and the final cake may be heat-sensitive, aseptic processing under Grade A conditions with ISO 14644-1 Class 5 is used. The reconstituted solution is tested for subvisible particulates by USP <788> with particle counts not more than 6,000 particles per vial at ≥10 µm and not more than 600 particles per vial at ≥25 µm; it is tested for bacterial endotoxins by USP <85>. Leachables from polyvinyl chloride containers may be elevated by the co-solvent fraction; non-DEHP polyethylene or elastomeric infusion lines are preferred and must be qualified under 21 CFR 211.94. The finished injectable is a lyophilized vial for reconstitution, not a ready-to-use infusion.

Oral Solution Co-Solvent Limits and Preservative Efficacy Control

A ready-to-use oral solution containing 9-fluorenemethanol pharma grade API is formulated at 1.0 mg/mL with PEG-400 25% v/v, glycerin 15% v/v, citrate buffer 20 mM at pH 4.5, methylparaben 0.18% w/v, propylparaben 0.02% w/v, and disodium edetate 0.05% w/v in purified water. Because the molecule is a neutral primary alcohol without a basic amine or carboxylic acid centre, pH-shift solubilization has negligible effect; the co-solvent fraction above 25% v/v is the primary solubilizing factor. The vehicle is heated to 40 °C to dissolve the parabens, then cooled to 25 °C before the API is dissolved in the PEG-400 phase. The pH is adjusted with 0.1 M HCl to 4.5 ± 0.2. The finished solution is filtered through 1.0 µm and 0.45 µm polypropylene filters and filled into amber glass bottles with child-resistant closures qualified by USP <671>. The preservative system is tested by the preservative efficacy test of USP <51> using category 4 criteria. The bottle packaging is selected because fluorenylmethanol-related compounds may be photosensitive. The terminal finished product is a 5 mL unit dose delivering 5 mg API. Gradient clinical manufacturing uses 21 CFR 211.101 component charge verification and 21 CFR 211.160 batch record review. Published data for this specific configuration are limited; the ratios shown are representative starting formulation parameters rather than regulatory-approved limits.